Comparative Predictive Performance of Serum and Dose-Normalized Valproate Levels for Seizure Control in Adults With...

Area of Science:

• Pharmacology and Neurology
• Clinical Therapeutics
• Epilepsy Management

Background:

• Valproate is a common antiepileptic drug with variable patient responses.
• Current dosing guidelines may not reliably predict seizure control.
• The predictive value of dose-normalized valproate levels for seizure outcomes is uncertain.

Purpose of the Study:

• To assess the predictive accuracy of serum valproate levels for seizure control.
• To compare serum levels with dose-normalized levels in predicting seizures.
• To determine if demographic factors improve seizure prediction models.

Main Methods:

• Secondary analysis of prospectively collected data from adult epilepsy patients on valproate monotherapy.
• Follow-up for one month to record seizure occurrence.
• Logistic regression and ROC analysis to evaluate serum valproate levels, dose-normalized levels, and multivariable models.

Main Results:

• Serum valproate levels showed strong predictive performance for seizure control (AUC: 0.891), with an optimal cutoff of 56.1 µg/mL.
• Dose-normalized levels had lower predictive performance (AUC: 0.829).
• Serum valproate levels were a significant predictor, while dose-normalized levels showed weaker associations.

Conclusions:

• Serum valproate levels offer a clinically relevant prediction of seizure control, superior to dose-normalized metrics.
• Concentration-based monitoring may aid in tailoring valproate therapy for individual epilepsy patients.
• Further research could validate these findings for routine clinical practice.